Maldotti Dalla Corte Bárbara, Medeiros Soares Nayron, de Carvalho Neto Eurípedes Gomes, de Mello Rieder Carlos Roberto
Medical Sciences Postgraduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
Front Neurol. 2025 Aug 19;16:1657824. doi: 10.3389/fneur.2025.1657824. eCollection 2025.
Autonomic symptoms are among the most important factors determining the quality of life in patients with Parkinson's disease (PD). This study aimed to assess the profile of autonomic dysfunction symptoms in three groups of patients with genetic PD, carrying mutations in , , and genes, compared with subjects with sporadic PD.
This case-control observational secondary analysis of prospectively collected data was performed on 742 patients (485 in the sporadic group, 165 in the LRRK2 group, 85 in the GBA group, and nine in the PRKN group). Autonomic symptoms were evaluated using the Scale for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT).
The GBA group exhibited more severe autonomic linsymptoms than the sporadic group, even after controlling for potential confounders such as disease duration and levodopa equivalent daily dose (linear regression B value = -4.668; Total SCOPA-AUT: = 0.050; LEDD: = 0.966; Disease Duration: = 0.498). The LRRK2 group initially showed more autonomic symptoms, but this did not remain significant after adjustment for disease duration ( value = -3.105; = 0.189). The PRKN group did not differ significantly from the sporadic group. Subgroup analysis highlighted specific issues including constipation, early satiety, and heat intolerance in both the GBA and LRRK2 groups, orthostatic hypotension in the GBA group and urinary incontinence and excessive perspiration in the LRRK2 group. Despite these subjective reports, objective assessment for orthostatic hypotension revealed no significant inter-group differences.
These findings that genetic background may influence the severity of autonomic dysfunction in PD. In particular, patients with mutations appear to experience a greater autonomic symptom burden, underscoring the need for personalized clinical monitoring and further research into genotype-specific disease progression. However, inconsistencies between subjective reports and objective autonomic measures emphasize the importance of employing more refined and sensitive assessment tools. Larger and demographically balanced cohorts are required to confirm these results, especially for the underpowered PRKN.
自主神经症状是决定帕金森病(PD)患者生活质量的最重要因素之一。本研究旨在评估携带、和基因 突变的三组遗传性PD患者与散发性PD患者相比的自主神经功能障碍症状特征。
对742例患者(散发性组485例、LRRK2组165例、GBA组85例、PRKN组9例)进行了这项对前瞻性收集数据的病例对照观察性二次分析。使用帕金森病自主神经功能结局量表(SCOPA-AUT)评估自主神经症状。
即使在控制了疾病持续时间和左旋多巴等效日剂量等潜在混杂因素后,GBA组的自主神经症状仍比散发性组更严重(线性回归B值 = -4.668;总SCOPA-AUT: = 0.050;LEDD: = 0.966;疾病持续时间: = 0.498)。LRRK2组最初表现出更多的自主神经症状,但在调整疾病持续时间后,这一差异不再显著(值 = -3.105; = 0.189)。PRKN组与散发性组无显著差异。亚组分析突出了一些特定问题,包括GBA组和LRRK2组的便秘、早饱感和不耐热,GBA组的体位性低血压以及LRRK2组的尿失禁和多汗。尽管有这些主观报告,但体位性低血压的客观评估显示组间无显著差异。
这些发现表明遗传背景可能影响PD患者自主神经功能障碍的严重程度。特别是,携带突变的患者似乎自主神经症状负担更重,这凸显了个性化临床监测以及对基因型特异性疾病进展进行进一步研究的必要性。然而,主观报告与客观自主神经测量之间的不一致强调了采用更精细和敏感评估工具的重要性。需要更大且人口统计学上均衡的队列来证实这些结果,特别是对于样本量不足的PRKN组。